• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Lupin receives FDA approval for generic Clobex lotion

expressbpdSeptember 27, 2017

Tag: lupin , FDA , Clobex lotion

It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations

Lupin has received final approval for its Clobetasol Propionate Lotion, 0.05 per cent from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories’ Clobex lotion, 0.05 per cent.

Lupin’s Clobetasol Propionate Lotion, 0.05 per cent is the AB rated generic equivalent of Galderma Laboratories’ Clobex lotion, 0.05 per cent. It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.

Previous:Clariant launches Amide/Amine-Free Anti-Static Concentrate for clean-room and API films

Next:Mithra and Libbs partner to commercialise Estelle oral contraceptive in Brazil

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Lupin receives FDA approval for generic Clobex lotion | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Mitomycin ( FDA)

Mitomycin ( FDA)
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Etoposide( FDA)

Etoposide( FDA)
Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals
Ramantadine( FDA)

Ramantadine( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service